Ascentage Pharma

Company snapshot

Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies and is in the process of conducting more than 40 clinical trials in specific regions worldwide. Ascentage Pharma has been listed on the Main Board of the HKEX with the stock code 6855.HK sin

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ascentage Pharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ascentage Pharma.

1. Jun 8, 2026 Clinical update

   Phase 1b: APG-115+pembrolizumab — Phase 2

2. May 26, 2026 Clinical update

   Olverembatinib — Phase 3

View all clinical trial activity →

• What is Ascentage Pharma?

  Ascentage Pharma Group is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ph+ ALL, Unresectable or Metastatic Melanoma or Advanced Solid Tumors. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity

• Is Ascentage Pharma publicly traded?

  Ascentage Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Ascentage Pharma develop or market?

  We link 3 drug profile(s) where Ascentage Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ascentage-pharma-group#company-drugs.

• What are the latest developments for Ascentage Pharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ascentage Pharma focus on?

  Ascentage Pharma focuses on Ph+ ALL, Unresectable or Metastatic Melanoma or Advanced Solid Tumors based on our analysis of their pipeline programs and drug development activities.